Upregulation of GAS5 can dramatically reverse cisplatin resistance in HCC cells by regulating miR-222 [52], whereas its downregulation can increase doxorubicin resistance in HCC cells by inhibiting the miR-21–PTEN signaling pathway [53]. This evidence concerns the gene GAS5 and hepatocellular carcinoma.